Comprehensive RNA Targeting Small Molecule Drug Discovery Market Forecast 2025-2034: Growth Trends and Strategic Shifts

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

RNA Targeting Small Molecule Drug Discovery Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of the RNA targeting small molecule drug discovery industry has seen a significant increase over the past few years. The market, which stood at $1.76 billion in 2024, is predicted to rise to $2.14 billion in 2025, with a compound annual growth rate (CAGR) of 21.8%. The growth during the historical period is largely due to the enhanced comprehension of disease genetics, advancements in genomics and proteomics, issues related to drug resistance, investment in biotech and pharma research, and the emergence of RNA therapeutics.

RNA Targeting Small Molecule Drug Discovery Market Size Forecast: What's the Projected Valuation by 2029?
The market for RNA targeting small molecule drug discovery is anticipated to experience tremendous growth over the next several years, propelling it to a worth of $4.92 billion by 2029. This represents a compound annual growth rate (CAGR) of 23.1%. The surge during the forecast period could be linked to the growth of RNA epigenetics research, RNA-seq and functional genomics, along with the inclusion of artificial intelligence (AI), the focus on patient-centric methodologies, and the use of exosome-mediated drug delivery. The forecast period is also likely to see key trends like the arrival of RNA editing technologies, progress in CRISPR technology, technological breakthroughs, advancements in RNA biology, and the application of RNA targeting in neurodegenerative diseases.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

What Are the Drivers Transforming the RNA Targeting Small Molecule Drug Discovery Market?
The rise in the number of cancer cases, genetic disorders, and viral infections is anticipated to fuel the expansion of the RNA-targeted small-molecule drug discovery market. Cancer consists of various diseases that involve the uncontrolled cell growth in our bodies. Viral infections are infections brought on by minuscule infectious cells unique to living organisms. RNA targeting-oriented drug discovery is employed to address cancer, genetic disorders, and viral infections as these conditions relate to genes and defective genetic materials. These ailments can be treated with drugs produced through RNA targeting-based techniques. Take the example of a report in February 2024 by the World Health Organization (WHO), a Switzerland-based global organization, which stated that there were nearly 20 million fresh cancer cases and 9.7 million deaths globally in 2022. Lung cancer had the highest incidence, with 2.5 million new cases (12.4%), followed by breast cancer in females (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, it is expected that there will be a 77% increase in new cancer cases, exceeding 35 million annually. Hence, the growing occurrence of cancer, genetic disorders, and viral infections is prompting the advancement of the RNA-targeted small-molecule drug discovery market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

What Long-Term Trends Will Define the Future of the RNA Targeting Small Molecule Drug Discovery Market?
The adoption of artificial intelligence (AI) in the process of drug discovery is becoming a prominent trend in the small-molecule drug discovery market. Major players in this particular market are utilizing AI technology to speed up drug discovery processes in order to maintain their market positions. As an example, Google Cloud, a product of the US-based technology firm Google, launched the Target and Lead Identification Suite along with the Multiomics Suite in May 2023 to assist the drug discovery procedure. The Multiomics Suite accelerates the analysis and identification of genetic information, aiding companies in the development of tailored medicines. Meanwhile, the Target and Lead Identification Suite helps researchers to obtain a deeper understanding of amino acids and predict protein structures.

Which Segments in the RNA Targeting Small Molecule Drug Discovery Market Offer the Most Profit Potential?
The RNA targeting small molecule drug discovery market covered in this report is segmented -

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies
3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:
1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition
2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA
3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways
4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

Which Firms Dominate the RNA Targeting Small Molecule Drug Discovery Market by Market Share and Revenue in 2025?
Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics

Which Regions Offer the Highest Growth Potential in the RNA Targeting Small Molecule Drug Discovery Market?
North America was the largest region in the RNA-targeting small molecule drug discovery market in 2024. The regions covered in the RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12480

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.